CN116425751B - Polycyclic compounds as MAT2A inhibitors - Google Patents
Polycyclic compounds as MAT2A inhibitors Download PDFInfo
- Publication number
- CN116425751B CN116425751B CN202211634333.0A CN202211634333A CN116425751B CN 116425751 B CN116425751 B CN 116425751B CN 202211634333 A CN202211634333 A CN 202211634333A CN 116425751 B CN116425751 B CN 116425751B
- Authority
- CN
- China
- Prior art keywords
- compound
- mat2a
- cancer
- reaction
- mtap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 title claims description 55
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 title claims description 55
- 239000003112 inhibitor Substances 0.000 title description 9
- 125000003367 polycyclic group Chemical group 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- -1 methoxyphenyl groups Chemical group 0.000 claims description 36
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 7
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 claims description 6
- 101150102751 mtap gene Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000004853 protein function Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- ZTNQNZDNHUAVEI-UHFFFAOYSA-N CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 Chemical compound CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 ZTNQNZDNHUAVEI-UHFFFAOYSA-N 0.000 abstract description 4
- 229940125535 MAT2A inhibitor Drugs 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 47
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 27
- 108030005627 S-methyl-5'-thioadenosine phosphorylases Proteins 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 239000012071 phase Substances 0.000 description 23
- 238000005481 NMR spectroscopy Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
- 229960001570 ademetionine Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 229930182817 methionine Natural products 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 6
- 108010007784 Methionine adenosyltransferase Proteins 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000007357 Methionine adenosyltransferase Human genes 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 150000002460 imidazoles Chemical class 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000006168 tricyclic group Chemical group 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010027406 Mesothelioma Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 3
- JTFITTQBRJDSTL-KVTDHHQDSA-N S-methyl-5-thio-alpha-D-ribose 1-phosphate Chemical compound CSC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H]1O JTFITTQBRJDSTL-KVTDHHQDSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 229940121649 protein inhibitor Drugs 0.000 description 3
- 239000012268 protein inhibitor Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- OOFWIULGXNWDQR-UHFFFAOYSA-N 2,6-dichloro-9-cyclohexylpurine Chemical compound C12=NC(Cl)=NC(Cl)=C2N=CN1C1CCCCC1 OOFWIULGXNWDQR-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- ODMQHYXPTUCRDC-UHFFFAOYSA-N 2-bromo-n-methyl-6-nitroaniline Chemical compound CNC1=C(Br)C=CC=C1[N+]([O-])=O ODMQHYXPTUCRDC-UHFFFAOYSA-N 0.000 description 2
- BVQOQXXITQULGQ-UHFFFAOYSA-N 3-bromo-2-n-methylbenzene-1,2-diamine Chemical compound CNC1=C(N)C=CC=C1Br BVQOQXXITQULGQ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 101000583944 Homo sapiens Methionine adenosyltransferase 2 subunit beta Proteins 0.000 description 2
- 101001055594 Homo sapiens S-adenosylmethionine synthase isoform type-1 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100030932 Methionine adenosyltransferase 2 subunit beta Human genes 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010079351 Tumor Suppressor Protein p14ARF Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- XZWQKJXJNKYMAP-UHFFFAOYSA-N cyclohexen-1-ylboronic acid Chemical compound OB(O)C1=CCCCC1 XZWQKJXJNKYMAP-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OAEABYNRBPCSQB-UHFFFAOYSA-N methyl 2-(bromomethyl)-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC=C1CBr OAEABYNRBPCSQB-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- HTXNALLULNQFDV-UHFFFAOYSA-N tert-butyl 5-amino-3-oxo-1h-isoindole-2-carboxylate Chemical compound C1=C(N)C=C2C(=O)N(C(=O)OC(C)(C)C)CC2=C1 HTXNALLULNQFDV-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- MWYFDHRLYOKUMH-UHFFFAOYSA-N 1-bromo-2-fluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Br)=C1F MWYFDHRLYOKUMH-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- HCTISZQLTGAYOX-UHFFFAOYSA-N 4,6-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=C(Cl)N=CN=C1Cl HCTISZQLTGAYOX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- ATXXLNCPVSUCNK-UHFFFAOYSA-N 5-bromo-2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Br)C=N1 ATXXLNCPVSUCNK-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- HPHHVCPTSPNXDW-UHFFFAOYSA-N C1(=CCCCC1)C=1C(=NN2C=1NC(=C(C2=O)C1=CC=C(C=C1)OC)NC=1C=NC=CC=1)C1=CC=CC=C1 Chemical compound C1(=CCCCC1)C=1C(=NN2C=1NC(=C(C2=O)C1=CC=C(C=C1)OC)NC=1C=NC=CC=1)C1=CC=CC=C1 HPHHVCPTSPNXDW-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 1
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 101100076569 Euplotes raikovi MAT3 gene Proteins 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 description 1
- 101001134276 Homo sapiens S-methyl-5'-thioadenosine phosphorylase Proteins 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 description 1
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 1
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- TVGKPVDDCDQBRC-UHFFFAOYSA-N methyl 2-methyl-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC=C1C TVGKPVDDCDQBRC-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 238000002531 positive electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 244000038651 primary producers Species 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- CAZVMZJHKVOJRZ-UHFFFAOYSA-N tert-butyl 5-nitro-3-oxo-1h-isoindole-2-carboxylate Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(C(=O)OC(C)(C)C)CC2=C1 CAZVMZJHKVOJRZ-UHFFFAOYSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- 125000006092 tetrahydro-1,1-dioxothienyl group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
- ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a compound shown in a formula I and an isomer or pharmaceutically acceptable salt thereof, a preparation method, a pharmaceutical composition and application of the compound as an MAT2A inhibitor.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and in particular relates to a polycyclic compound serving as an MAT2A inhibitor and an isomer thereof, or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition and application thereof in preparation of drugs for treating cancers in subjects suffering from the cancers.
Background
Methionine Adenosyltransferase (MAT) (also known as S-adenosylmethionine synthetase) is a cellular enzyme that catalyzes the synthesis of S-adenosylmethionine (SAM or AdoMet) from methionine and ATP; this catalysis is considered to be the rate limiting step in methionine recycling. SAM is the propylamino donor in polyamine biosynthesis and is the primary methyl donor for DNA methylation and is involved in gene transcription and cell proliferation and production of secondary metabolites.
Three subtypes of human MAT include MAT1 and MAT3 expressed in liver tissue, while MAT2A is ubiquitously expressed in human cell types, the predominant form in human tumors. Crystal structure and mechanism studies showed that despite their 85% identity in amino acid sequence, there was a significant difference in their mechanism of action. MAT2A forms a functional homodimer in its purified active form and binds to the regulatory protein MAT 2B. MAT2B modulated MAT2A activity by increasing the sensitivity of MAT2A to ADOMet product inhibition, but did not provide significant rate enhancement. Cell localization studies showed that MAT2A was present in both the cytoplasm and nucleus. Nuclear concentration of MAT2A was reported to occur during replication and subsequent G2 phase, meeting the highly methylated requirements of DNA and histone methylation processes within the S phase nuclei. The activity of ADOMet in the transmethylation reaction has been identified as a rate limiting factor in the development of lung cancer stem cells, making MAT2A and the enzymes involved in methionine circulation targets for anticancer drugs. Methionine production of ADOMet by MAT2A comes from a dietary source or polyamine cycle in which 5-methylthio-D-ribose 1-phosphate produced by S-methyl-5' -thioadenylate phosphorylase is cycled to methionine. MAT2A protein has been reported to have increased expression in cancers such as colon cancer, liver cancer, stomach cancer, blood and liver. About 15% of human cancers show a deletion of the MTAP (S-methyl-5' -thioadenosine phosphorylase) gene and thus lack the methionine recovery pathway for polyamine synthesis. The deletion of MTAP in chr9p21 typically includes a deletion of the CDKN2a oncogene locus. Comprehensive genetic lethality studies of MATP-/-cancer cells indicate that inhibition of MAT2A, PRMT5 and PRMT1 by these cancer cells increases sensitivity.
In hepatocellular carcinoma (HCC), down-regulation of MAT1A and up-regulation of MAT2A occur, which is called MAT1A: MAT2A conversion. The shift accompanied by the up-regulation of MAT2B results in lower SAM content, which provides a growth advantage for hepatoma cells. MAT2A is a target of anti-tumor therapy because it plays a vital role in promoting liver cancer cell growth. Recent studies have shown that silencing by using small interfering RNAs substantially inhibits the growth of hepatoma cells and induces apoptosis. See, e.g., T.Li et al, J.cancer 7 (10) (2016) 1317-1327.
Some MTAP-deficient cancer Cell lines are particularly sensitive to inhibition of MAT2A, marjon et al (Cell Reports15 (3) (2016) 574-587). MTAP (methylthioadenosine phosphorylase) is an enzyme widely expressed in normal tissues, which catalyzes the conversion of Methylthioadenosine (MTA) to adenine and 5-methylthioribose-1-phosphate. Adenine is remedied to produce adenosine monophosphate, and 5-methylthioribose-1-phosphate is converted to methionine and formate. Because of this salvage pathway, MTA can be an alternative source of purine when de novo synthesis of purine is blocked by, for example, antimetabolites such as L-alacinone.
In other cancers lacking MTAP deletions (including hepatocellular carcinoma and leukemia), MAT2A is deregulated. Cai et al, cancer Res.58 (1998) 1444-1450; T.S. Jani et al, cell.Res.19 (2009) 358-369. Silencing MAT2A expression by RNA interference can produce antiproliferative effects in a variety of cancer models, H.Chen et al, gastroenterology133 (2007)
207-218; liu et al hepatol Res.37 (2007) 376-388.
Many human and murine malignant cells lack MTAP activity. MTAP deficiency is present not only in tissue culture cells, but also in primary leukemias, gliomas, melanomas, pancreatic cancers, non-small cell lung cancer (NSCLC), bladder cancers, astrocytomas, osteosarcomas, head and neck cancers, myxochondrosarcoma, ovarian cancers, endometrial cancers, breast cancers, soft tissue sarcomas, non-hodgkin lymphomas and mesothelioma. The gene encoding human MTAP is located in region 9p21 on human chromosome 9 p. This region also contains the tumor suppressor genes p16.sup.INK4A (also known as CDKN 2A) and p15.sup.INK4B. These genes encode p16 and p15, which are inhibitors of cyclin D-dependent kinases cdk4 and cdk6, respectively.
Alternatively, the p16.sup.INK4A transcript may be an open reading frame (ARF) spliced into a transcript encoding pl4 ARF. p14ARF binds to MDM2 and prevents degradation of p53 (Pomerantz et al (1998) Cell 92:713-723). The 9p21 chromosomal region is of interest because it is often homozygous for deletion in a variety of cancers, including leukemia, NSLC, pancreatic cancer, glioma, melanoma, and mesothelioma. Deletions typically inactivate more than one gene. For example, cairns et al ((1995) Nat. Gen.11:210-212) reported that after more than 500 primary tumors were studied, almost all deletions identified in these tumors involved a 170kb region containing MTAP, p14ARF and Pl6INK 4A. Carson et al (WO 99/67134) reported a correlation between the stage of tumor development and loss of homozygosity of the gene encoding MTAP and the gene encoding p 16. For example, the deletion of the MTAP gene, not p16.sup.INK4a, is reported to be predictive of cancer in the early stages of development, whereas the deletion of the genes encoding p16 and MTAP is reported to be predictive of cancer in the more advanced stages of cancer development. In some osteosarcoma patients, the MTAP gene is present at the time of diagnosis, but is deleted at a later point in time (Garcia-Castellano et al, clin.cancer Res.8 (3) 2002 782-787).
MAT2A enzyme inhibitors for the treatment of cancer are disclosed in WO 2018039972; WO2021158792 mentions MAT2A inhibitors for the treatment of autoimmune or inflammatory diseases; MAT2A enzyme inhibitors for the treatment of diseases or conditions mediated by overexpression of MAT2A are described in WO 2018045071; also disclosed in CN202080014106.0 is the compound 3- (cyclohex-1-en-1-yl) -6- (4-methoxyphenyl) -2-phenyl-5- (pyridin-3-ylamino) pyrazolo [1,5-a ] pyrimidin-7 (4H) -one for the treatment of MTAP-deficient non-small cell lung cancer (NSCLC) in a patient in need thereof; CN114874207a discloses MAT2A inhibitors of 6-and 6-ring parent nuclei; CN113999232a discloses polycyclic compounds that inhibit MTAP-deleted cancer cells.
Finding effective MAT2A inhibitors is an important direction in the development of current tumor-targeted drugs. .
Disclosure of Invention
Summary of The Invention
The present invention meets the significant need for safe and effective compounds and methods for treating, preventing, and managing cancer while reducing or avoiding the toxicity and/or side effects associated with conventional therapies. In order to solve the technical problems, the invention adopts the following technical scheme:
in one aspect, the present invention provides compounds of formula I and isomers thereof, or pharmaceutically acceptable salts thereof,
Wherein:
R 1 selected from the group consisting of absence, C 6 -C 10 Aryl, C 6 -C 10 Aryl is optionally substituted with one or more substituents selected from the group consisting of: hydroxy, halogen, -NH 2 、-CN、C 1 -C 6 -alkyl, C 1 -C 6 -an alkoxy group;
R 2 selected from hydrogen, hydroxy, halogen, -NH 2 、-CN、C 1 -C 6 -alkyl, C 1 -C 6 -an alkoxy group;
R 3 selected from the group consisting of absence, C 6 -C 10 Aryl optionally substituted with one or more substituents selected from the group consisting of: hydroxy, halogen, -NH 2 、-CN、C 1 -C 6 -alkyl, C 1 -C 6 -an alkoxy group;
R 4 selected from hydroxy, C 6 -C 12 Aryl, C 6 -C 12 Heteroaryl, C 6 -C 12 Heterocyclyl, each optionally substituted with one or more substituents selected from the group consisting of: hydroxy, halogen, -NH 2 Carboxyl, -CN, C 1 -C 6 -alkyl, C 1 -C 6 -an alkoxy group;
R 5 selected from C 2 -C 6 -alkenyl, C 2 -C 6 -cycloalkenyl, C 6 -C 12 Aryl, C 6 -C 12 Heteroaryl, C 6 -C 12 Heterocyclyl, each optionally substituted with one or more substituents selected from the group consisting of: hydroxy, halogen, -NH 2 Carboxyl, -CN, C 1 -C 6 -alkyl, C 1 -C 6 -an alkoxy group;
R 6 selected from hydrogen, NR 1a R 1b ,NR 1a R 1b Optionally substituted with one or more substituents selected from the group consisting of: hydroxy, halogen, -NH 2 Carboxyl, -CN, C 1 -C 6 -alkyl, C 1 -C 6 -an alkoxy group;
R 1a 、R 1b each independently selected from hydrogen, C 5 -C 12 Aryl, C 5 -C 12 Heteroaryl, C 5 -C 12 A heterocyclic group.
Further, the R 1 Selected from the group consisting of absent, methoxyphenyl.
Further, the R 2 Selected from the group consisting ofHydrogen, hydroxy; r is R 3 Selected from the group consisting of absent, methoxyphenyl.
Further, the R 4 Selected from hydroxyl groups and the following structures:
the groups are optionally substituted with one or more amino, methyl, methoxy, hydroxy, halogen, cyano groups.
Further, the R 5 Selected from cyclohexene, cyclohexadiene and the following structures:
the groups are optionally substituted with one or more amino, methyl, methoxy, hydroxy, halogen, cyano groups.
Further, the R 6 Selected from hydrogen,The radicals optionally being substituted by one or more hydroxy, halogen, -NH 2 Carboxyl, -CN, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy substitution.
The invention also provides compounds represented by the following formulas (I-a), (I-b) and (I-c) and isomers thereof, or pharmaceutically acceptable salts thereof,
R 4 、R 5 is defined as above.
The present invention also provides a compound, or an isomer thereof, or a pharmaceutically acceptable salt thereof, which is:
the invention also provides a pharmaceutical composition, which comprises the compounds shown in the formula (I), (I-a), (I-b), (I-c) and the like, isomers thereof or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable auxiliary materials.
The invention also provides the use of a compound comprising formula (I), (I-a), (I-b), (I-c), etc., or an isomer thereof, or a pharmaceutically acceptable salt thereof, or the composition, in the manufacture of a medicament for treating a disease or disorder in a subject suffering from said disease or disorder, wherein said disease or disorder is mediated by overexpression of MAT2A, preferably a cancer, characterized by a reduction or absence of expression of the methylthioadenosine phosphorylase (MTAP) gene, a deletion of the MTAP gene, or a reduction of MTAP protein function.
The inventor discovers that the compound is a high-efficiency MAT2A inhibitor, has extremely strong MAT2A inhibition activity, and can be used for preparing the drugs for preventing and/or treating the indications related to MAT2A inhibition, including cancers caused by reduction or deletion of MTAP expression, deletion of MTAP genes and reduction of MTAP protein functions. The present invention has been completed based on the above findings.
Detailed Description
Various aspects and features of the invention are described further below.
All documents cited herein are incorporated by reference in their entirety and are incorporated by reference herein to the extent they are not inconsistent with this invention. Furthermore, various terms and phrases used herein have a common meaning known to those skilled in the art, and even though they are still intended to be described and explained in greater detail herein, the terms and phrases used herein should not be construed to be inconsistent with the ordinary meaning in the sense of the present invention. The following are definitions of various terms used in the present invention, which are applicable to terms used throughout the specification of the present application, unless otherwise specified in the specific context.
The compounds according to the invention may exist in tautomeric forms, the invention then embraces all tautomeric forms.
The compounds of the present invention have asymmetric centers and the compounds of the present invention containing an asymmetrically substituted atom can be isolated in optically active or racemic forms, and one skilled in the art knows how to prepare optically active forms, such as by racemate resolution or synthesis from optically active starting materials. Unless a specific stereochemistry or isomeric form is specifically indicated, the present invention includes all chiral, diastereomeric and racemates. Methods for preparing the compounds of the invention and intermediates thereof are part of the present invention. All tautomers of the compounds of the invention are also part of the invention.
The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
The term "substituted" means that any one or more hydrogen atoms on a particular atom or group is substituted with a substituent, provided that the valence of the particular atom is normal and the resulting compound is stable after substitution. When the substituent is =o, it means that two hydrogen atoms are substituted. When a plurality of hydrogen atoms are substituted with substituents, each substituent may be the same substituent or different substituents, independently of the other. The kind and number of substituents may be arbitrary on the basis that they can be chemically achieved unless otherwise specified.
The terms "alkoxy" and "alkylamino" are used in conventional sense to refer to an alkyl group attached to the remainder of the molecule through an oxygen atom or amino group, respectively, wherein alkyl is as described herein.
As used herein, the term "halogen", "halo", and the like, means fluorine, chlorine, bromine, or iodine, particularly fluorine, chlorine, bromine, and particularly preferably fluorine, chlorine.
As used herein, the term "alkyl" refers to an alkyl group having the indicated number of carbon atoms, which is a straight or branched chain alkyl group, and which may include its sub-groups, e.g., reference to "C 1 -C 6 Alkyl "when it may also include C 1 -C 4 Alkyl, C 1 -C 3 Alkyl, C 2 -C 6 Alkyl, C 2 -C 4 Alkyl groups, etc., and specific groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, etc. It may be divalent, e.g. methylene, ethylene.
Representing a single bond or a double bond.
The terms "heterocycle", "heterocyclic" or "heterocyclyl" are used interchangeably and refer to substituted and unsubstituted 3 to 7 membered monocyclic groups, 7 to 11 membered bicyclic groups, and 10 to 15 membered tricyclic groups having at least one heteroatom (O, S or N) in at least one ring, said heteroatom-containing ring preferably having 1, 2 or 3 heteroatoms selected from O, S and N. Each ring of such heteroatom-containing groups may contain one or two oxygen or sulfur atoms and/or one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen atoms may optionally be quaternized. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or fully unsaturated. The heterocyclic group may be attached to any available nitrogen or carbon atom. As used herein, the terms "heterocycle", "heterocycloalkyl", "heterocycle", and "heterocyclyl" include "heteroaryl" groups, as defined below.
"aryl" when used alone or as part of another termRefers to carbocyclic aromatic groups, whether fused or not, having the indicated number of carbon atoms, or up to 14 carbon atoms if the number of carbon atoms is not indicated, e.g. C 6 -C 14 -aryl. Specific aryl groups are phenyl, naphthyl, biphenyl, phenanthryl, tetracenyl, and the like.
In addition to heteroaryl groups described below, exemplary monocyclic heterocyclic groups include azetidinyl, pyrrolidinyl, oxetanyl, imidazolinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, 1-pyridonyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1, 3-dioxolane, and tetrahydro-1, 1-dioxothienyl, and the like. Exemplary bicyclic heterocyclic groups include quinuclidinyl.
The term "heteroaryl" refers to substituted and unsubstituted aromatic 5-or 6-membered monocyclic groups, 9-or 10-membered bicyclic groups, and 11-to 14-membered tricyclic groups having at least one heteroatom (O, S or N) in at least one ring, said heteroatom-containing ring preferably having 1, 2 or 3 heteroatoms selected from O, S and N. Each ring of the heteroaryl group containing a heteroatom may contain one or two oxygen or sulfur atoms and/or one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen atoms may optionally be quaternized. Heteroaryl groups as bicyclic or tricyclic must include at least one fully aromatic ring, but the other fused ring or rings may be aromatic or non-aromatic. Heteroaryl groups may be attached to any available nitrogen or carbon atom of any ring. Where valence allows, if the other ring is cycloalkyl or heterocycle, it is additionally optionally substituted with =o (oxo).
Unless otherwise indicated, when referring to a specifically named aryl (e.g., phenyl), heterocyclyl (e.g., pyrrolidinyl, piperidinyl, and morpholinyl), or heteroaryl (e.g., tetrazolyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, and furanyl), the reference is intended to include rings optionally having 0 to 3, preferably 0 to 2 substituents selected from the substituents listed above for aryl heterocyclyl and/or heteroaryl.
As used herein, the term "pharmaceutically acceptable salt" means a salt which is not only physiologically acceptable to the subject, but also refers to a synthetic substance of pharmaceutical use, such as a salt formed as an intermediate in the preparation of chiral resolution, which salt may play a role in obtaining the end product of the present invention, although it is not directly administered to the subject. Specifically included are acid (organic and inorganic) addition salts or base addition salts (including organic and inorganic bases).
As used herein, the term "disease" refers to a physical state of the subject that is associated with the disease of the present invention. For example, the arterial peripheral disease and the neurodegenerative related disease according to the present invention.
The cancers of the invention include standard treatments such as surgery, radiation therapy, chemotherapy, hormonal therapy, and the like.
"cancer" or "malignancy" refers to any of a variety of diseases characterized by uncontrolled cellular abnormal proliferation, the ability of affected cells to spread locally or through the blood stream and lymphatic system to other sites, the body (i.e., metastasis), and any of a number of characteristic structures and/or molecular features. "cancer cells" refers to cells that undergo early, mid, or late stages of multistep tumor progression. Cancers include mesothelioma, neuroblastoma, rectal cancer, colon cancer, familial adenomatous polyposis cancer and hereditary non-polyposis colorectal cancer, esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, gastric cancer, adenocarcinoma, medullary thyroid cancer, papillary thyroid cancer, renal parenchymal cancer, ovarian cancer, cervical cancer, endometrial cancer, choriocarcinoma, pancreatic cancer, prostate cancer, bladder cancer, testicular cancer, breast cancer, urinary system cancer, melanoma, brain tumor, head and neck cancer, acute Lymphoblastic Leukemia (ALL), chronic Lymphocytic Leukemia (CLL), acute Myelogenous Leukemia (AML), chronic Myelogenous Leukemia (CML), hepatocellular carcinoma, gallbladder cancer, bronchogenic carcinoma, advanced solid tumors, small cell lung cancer, metastatic non-small cell lung cancer, multiple myeloma, basal cell tumor, teratocarcinoma, retinoblastoma, choriocarcinoma, seminoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, sarcomas, fibrosarcoma, sarcomas, and lymphomas of the pancreas, and sarcomas.
The compound of the present invention or a pharmaceutical composition containing the same may be administered in unit dosage form by the enteral or parenteral route such as oral, intravenous, intramuscular, intravenous, subcutaneous, nasal, oral mucosal, ocular, pulmonary and respiratory tract, skin, vaginal, rectal, etc.
The dosage form may be a liquid, solid or semi-solid dosage form. The liquid preparation can be solution (including true solution and colloid solution), emulsion (including o/w type, w/o type and multiple emulsion), suspension, injection (including injection solution, powder injection and transfusion), eye drop, nasal drop, lotion, liniment, etc.; the solid dosage forms can be tablets (including common tablets, enteric coated tablets, buccal tablets, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules and enteric coated capsules), granules, powder, micropills, dripping pills, suppositories, films, patches, aerosol (powder) and sprays; the semisolid dosage form may be an ointment, gel, paste, or the like.
For the purpose of administration, the drug or the pharmaceutical composition of the present invention can be administered by any known administration method to enhance the therapeutic effect.
The compounds or compositions of the present invention may be administered alone or in combination with other therapeutic or symptomatic agents. When the compound of the present invention has a synergistic effect with other therapeutic agents, its dosage should be adjusted according to the actual circumstances.
The solvents used in the present application are commercially available. The abbreviations used in this application are as follows:
table 1: abbreviation meaning
Beneficial technical effects
The inventor discovers that the compound has good MAT2A inhibition activity, and the IC50 is smaller than that of a positive control medicine AG270. The invention provides MAT2A inhibitor compounds with novel structures and strong activity, and the compounds have good application prospects in prevention and/or treatment of MAT2A inhibition related indications such as MTAP expression reduction or deletion, MTAP gene deletion, MTAP protein function reduction and the like.
Detailed Description
The following examples are presented to aid one skilled in the art in better understanding the present invention, but the scope of the present invention is not limited thereto.
For all of the following examples, standard procedures and methods known to those skilled in the art may be used. Unless otherwise indicated, all temperatures are expressed in degrees Celsius. The structure of the compounds is determined by nuclear magnetic resonance spectroscopy (NMR) and/or Mass Spectrometry (MS).
The structure of the compounds of the invention is determined by Nuclear Magnetic Resonance (NMR) or/and liquid-mass spectrometry (LC-MS). NMR chemical shift (δ) is in parts per million (ppm). Nuclear magnetic resonance was measured using a Bruker avance-400 nuclear magnetic resonance apparatus with deuterated dimethyl sulfoxide (DMSO-d 6), deuterated methanol (CD 3 OD) and deuterated chloroform (CDCl 3) as solvents, and Tetramethylsilane (TMS) as internal standard.
Liquid phase mass spectrometry LC-MS the liquid phase fraction was measured using an ACQUITY UPLC ultra high pressure liquid chromatograph and the mass spectrum fraction was measured using a Xex og2-Sqtof mass spectrometer.
The starting materials in the examples of the present invention are known and commercially available, and may also be used or synthesized according to methods known in the art.
Example 1:7- (4-methoxyphenyl) -9- (3-oxoisoindol-5-yl) -7, 9-dihydro-8H-purin-8-one (Compound 1)
Step 1: synthesis of Compound 1-1
Methyl 2-methyl-5-nitrobenzoate (40.00 g,205.12mmol,1.0 eq.) N-bromosuccinimide (91.28 g,512.82mmol,2.50 eq.) and azobisisobutyronitrile (6.72 g,41.02mmol,0.2 eq.) were added to carbon tetrachloride (200 ml) solvent and reacted at 80℃for 16 hours. After the reaction, water and methylene chloride were added to extract, the organic phase was dried over anhydrous sodium sulfate, and the mixture was separated and purified by a normal phase column, and when the polarity was 12%, the product was eluted and concentrated to give methyl 2- (bromomethyl) -5-nitrobenzoate as a yellow solid (30.00 g,53.57% yield). LCMS (TOF MS ES) + )m/z[M+H] + :274/276。
1H NMR(400MHz,CDCl3)δ9.00(d,J=2.2Hz,1H),8.34(d,J=2.3Hz,1H),7.96(s,1H),4.97(s,2H),1.57(s,3H).
Step 2: synthesis of Compounds 1-2
Methyl 2- (bromomethyl) -5-nitrobenzoate (27.3 g,100.0mmol,1.0 eq) was added to a solution of ammonia-methanol (500 mL,7 mol/L) and reacted at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated, ethyl acetate (100 mL) was added and stirred for 10 minutes, and then, the mixture was filtered, and the cake was washed twice with ethyl acetate (50 mL), and the solid was collected to give 6-nitroiso Xin Duolin-1-one (13.0 g,73.00% yield) as a yellow solid. LCMS (TOF MS ES) + )m/z[M+H] + :179.04。
Step 3: synthesis of Compounds 1-3
The compound 6-nitroiso Xin Duolin-1-one (13.0 g,73.03mmol,1.0 eq.) was added to a solution of di-tert-butyl dicarbonate (31.80 g,146.06mmol,2.0 eq.) and triethylamine (22.17 g,219.12mmol,3.0 eq.) in dichloromethane (250 ml) and 4-dimethylaminopyridine (1.78 g,14.60mmol,0.2 eq.) was slowly added under ice-bath conditions at room temperature for 16 hours. After completion of the reaction, the reaction mixture was added to water, extracted three times with dichloromethane (100 ml), the organic layers were combined and washed with saturated brine, respectivelyWashing, drying with anhydrous sodium sulfate, filtering, concentrating the filtrate, separating and purifying by normal phase column, petroleum ether and ethyl acetate system, eluting with 25% polarity, and concentrating to obtain yellow solid tert-butyl 6-nitro-1-oxo-isoindole-2-carboxylate (9.0 g, 44.34%). LCMS (TOF MS ES) + )m/z[M+H] + :279.04。 1 H NMR(400MHz,DMSO)δ8.55(dd,J=8.4,2.2Hz,1H),8.42(d,J=2.1Hz,1H),7.94(d,J=8.4Hz,1H),4.93(s,2H),1.53(s,9H).
Step 4: synthesis of Compounds 1-4
The compound tert-butyl 6-nitro-1-oxoisoindole-2-carboxylate (9.0 g,32.37mmol,1.0 eq.) was added to a methanol solution (200 mL), followed by Pd/C (1.10 g) and reacted for 16 hours at room temperature under hydrogen protection. After the reaction was completed, celite was rapidly filtered, and the filter cake was washed with methanol, and the filtrate was concentrated to give the crude product, tert-butyl 6-amino-1-oxoisoindole-2-carboxylate (7.80 g,97.0% yield), which was used directly in the next reaction. LCMS (TOF MS ES) + )m/z[M+H] + :249.12。
Step 5: synthesis of Compounds 1-5
Tert-butyl 6-amino-1-oxoisoindole-2-carboxylate (7.8 g,31.40mmol,1.0 eq.) and 4, 6-dichloro-5-nitropyrimidine (9.15 g,47.17mmol,1.50 eq.) were added to a solution of tetrahydrofuran (120 mL) and reacted at room temperature for 16 hours. After the completion of the reaction, the reaction mixture was added to water, extracted three times with methylene chloride (100 ml), the organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, the normal phase column was separated and purified, methylene chloride and ethyl acetate were separated and purified, and when the polarity was 10%, the product was eluted, and concentrated to give 6- [ (6-chloro-5-nitropyrimidin-4-yl) amino as a yellow solid]-1-oxo-isoindole-2-carboxylic acid tert-butyl ester (7.8 g,61.33% yield). LCMS (TOF MS ES) + )m/z[M+H] + :406.08。 1 H NMR(400MHz,DMSO-d 6 )δ10.38(s,1H),8.60(s,1H),7.84(s,1H),7.74(d,J=9.3Hz,1H),7.67(d,J=8.5Hz,1H),4.76(s,2H),1.49(s,9H).
Step 6: synthesis of Compounds 1-6
By reacting 6- [ (6-chloro-5-nitropyrimidin-4-yl) amino group]-1-oxoisoindolesTert-butyl indole-2-carboxylate (7.8 g,19.26mmol,1.0 eq.) was added to a methanol solution (200 mL) followed by Pd/C (1.10 g) and reacted at room temperature under hydrogen protection for 40 hours. After the reaction is completed, the diatomite is quickly filtered, a filter cake is washed by methylene dichloride/methanol (10:1), the filtrate is concentrated, a normal phase column is used for separation and purification, methylene dichloride and methylene dichloride/methanol (10:1) systems, when the polarity is 80%, a product flows out, and the product is concentrated to obtain brown solid 6- [ (5-aminopyrimidin-4-yl) amino ]-tert-butyl 1-oxoisoindole-2-carboxylate (1.2 g,18.27% yield). LCMS (TOF MS ES) + )m/z[M+H] + :342.15。 1 H NMR(400MHz,DMSO-d 6 )δ8.74(s,1H),8.19(d,J=1.8Hz,1H),8.16(s,1H),7.93(s,1H),7.80(dd,J=8.5,1.9Hz,1H),7.71(d,J=8.5Hz,1H),5.34(s,2H),4.79(s,2H),1.54(s,9H).
Step 7: synthesis of Compounds 1-7
Tert-butyl 6- [ (5-aminopyrimidin-4-yl) amino ] -1-oxoisoindole-2-carboxylate (200 mg,0.58mmol,1.0 eq.) was added to a solution of dichloromethane (5 mL), and a solution of triethylamine (120.0 mg,1.17mmol,2.0 eq.) and BTC (260 mg,0.87mmol,1.50 eq.) in dichloromethane were added sequentially at 0deg.C and reacted under nitrogen for 1 hour at 0deg.C. After completion of the reaction, the mixture was purified by column chromatography to give tert-butyl 1-oxo-6- (8-oxo-7, 8-dihydro-9H-purin-9-yl) isoindole-2-carboxylate (280 mg, crude) as a white solid. Directly used in the next reaction. LCMS (TOF MS ES+) M/z [ M+H ] +:368.13/312.13.
Step 8: synthesis of Compound 1
Tert-butyl 1-oxo-6- (8-oxo-7, 8-dihydro-9H-purin-9-yl) isoindole-2-carboxylate (280 mg,0.76mmol,1.0 eq.) 4-methoxyphenylboronic acid (695.4 mg,4.58mmol,6.0 eq.) anhydrous copper acetate (206.4 mg,1.14mmol,1.5 eq.) and anhydrous pyridine (180.4 mg,2.28mmol,3.0 eq.) were added to a solution of anhydrous N, N-dimethylformamide (8 mL) and reacted at room temperature under oxygen protection for 16 hours. After the completion of the reaction, the reaction mixture was filtered, the filter cake was washed with methanol, and the filtrate was concentrated and then added to ethyl acetate (50 mL), and then washed with water and saturated brine, dried over anhydrous sodium sulfate, and the filtrate was concentrated after filtration. Prep-HPLC preparation of white solid 7- (4-methoxyphenyl) -9- (3-oxoisoindol-5-yl) -7, 9-dihydro-8H-purine-8 Ketone (13.4 mg, 10.17%). LCMS (TOF MS ES) + )m/z[M+H] + :374.13. 1 H NMR(400MHz,DMSO-d 6 )δ8.71(d,J=5.3Hz,1H),8.36(s,1H),7.95(s,1H),7.92–7.81(m,2H),7.65–7.56(m,2H),7.22–7.11(m,2H),4.49(s,2H),3.85(s,3H).
Example 2:9- (cyclohex-1, 5-dien-1-yl) -1- (4-methoxyphenyl) -8-phenyl-2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (Compound 2)
Step 1: synthesis of Compound 2-1
2, 6-dichloropurine (21.77 g,115.0mmol,1.0 eq), cyclohexene-1-boronic acid (17.28 g,138mmol,1.2 eq), anhydrous copper acetate (25.0 g,138.0mmol,1.2 eq), triethylamine (58.3 g,576.0mmol,5.0 eq) were dissolved in 500mL dichloromethane and stirred at room temperature for 2 hours and minutes under air protection. After completion of the reaction, celite was filtered, and the filtrate was concentrated. Separating with normal phase column, petroleum ether and ethyl acetate system with polarity of 40% to obtain 2, 6-dichloro-9-cyclohexyl-9H-purine (3.3 g,10.71% yield), 1 H NMR(400MHz,DMSO-d 6 )δ8.79(s,1H),6.28(s,1H),2.56(s,2H),2.23(m,J=6.6Hz,2H),1.82–1.74(m,2H),1.64(m,J=6.3Hz,2H).
step 2: synthesis of Compound 2-2
2, 6-dichloro-9-cyclohexyl-9H-purine (2.7 g,10.0mmol,1.0 eq) was dissolved in tetrahydrofuran (10 mL), followed by addition of aqueous sodium hydroxide (1.0g,25.0mmol,l2.5 eq,30wt%) and reacted at room temperature for 16 hours. After the reaction is completed, 20mL of ethyl acetate is added, the organic layer is separated, filtered, washed by ethyl acetate and the solid is collected to obtain 2-Chloro-9-cyclohexyl-1, -dihydropyran-6-one (1.46 g,58.20% yield). 1 H NMR(400MHz,DMSO-d 6 )δ7.74(s,1H),6.20–6.13(m,1H),2.55(t,J=3.4Hz,2),2.20(m,J=6.6,3.4Hz,2H),1.81–1.75(m,2H),1.65–1.61(m,2H).
Step 3: synthesis of Compound 2-3
2-chloro-9-cyclohexyl-1, -dihydropyran-6-one (1.46 g,5.82mmol,1.0 eq), 2-aminopyridine (1.10 g,11.68mmol,2.0 eq), xant-Phos (1.01 g,1.75mmol,0.3 eq), palladium acetate (260.7 mg,1.16mmol,0.2 eq), cesium carbonate (3.77 g,11.60mmol,2.0 eq) were dissolved in a 1, 4-dioxane solution (50 mL), and reacted under nitrogen at 120℃for 16 hours. After completion of the reaction, celite was filtered, and the filtrate was concentrated, and the system was separated by a normal phase column (dichloromethane/(dichloromethane: methanol (10:1)) to give 9-cyclohexyl-1-en-1-yl-2-pyridin-2-amino-1, 9-dihydro-6H-purin-6-one (840 mg,47.42% yield) at a polarity of 60%, LCMS (ESI) [ M+H]+:309.14。 1 H NMR(400MHz,DMSO-d 6 )δ13.39(d,J=6.9Hz,1H),10.69(d,J=3.2Hz,1H),8.36(dd,J=5.3,1.7Hz,1H),7.93(s,1H),7.87–7.79(m,1H),7.28(d,J=8.5Hz,1H),7.10(dd,J=7.2,5.2Hz,1H),6.18(td,J=3.9,1.9Hz,1H),2.57(td,J=6.0,2.3Hz,2H),2.23(dq,J=6.6,3.5Hz,2H),1.85–1.79(m,2H),1.68–1.62(m,2H)。
Step 4: synthesis of Compounds 2-4
9-cyclohexyl-1-en-1-yl-2-pyridin-2-amino-1, 9-dihydro-6H-purin-6-one (840 mg,2.76mmol,1.0 eq), p-methoxyphenylboronic acid (4.2 g,27.6mmol,10.0 eq), anhydrous copper acetate (749.3 mg,4.14mmol,1.5 eq) were dissolved in anhydrous DMF (25 ml), and then anhydrous pyridine (872.0 mg,11.04mmol,4.0 eq) was added and reacted at room temperature under oxygen protection for 16 hours. After the reaction is completed, filtering, washing filter cake with methanol, collecting solid to obtain9-cyclohexyl-1-en-1-yl-1- (4-methoxyphenyl) -2-pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (660 mg,57.97% yield). 1 H NMR(400MHz,DMSO-d 6 )δ9.50(s,1H),8.28(s,1H),8.21(s,1H),7.71(s,1H),7.35(d,J=8.3Hz,1H),7.29–7.21(m,2H),7.09–6.99(m,2H),6.89(s,1H),6.37(s,1H),3.82(d,J=2.2Hz,2H),2.66(d,J=7.2Hz,2H),2.26(s,2H),1.81(q,J=6.0Hz,2H),1.66(t,J=6.1Hz,2H)。
Step 5: synthesis of Compounds 2-5
N-bromosuccinimide (859.9 mg,4.83mmol,4.0 eq) was added to a solution of 9-cyclohexyl-1-en-1-yl-1- (4-methoxyphenyl) -2-pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (500.0 mg,1.21mmol,1.0 eq) in dichloromethane (5 mL) and reacted at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated, and the mixture was separated by a normal phase column to give 8-bromo-9- (3-bromocyclohexyl-1-en-1-yl) -1- (4-methoxyphenyl) -2-pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (250 mg,36.12% yield) at a polarity of 35%. LCMS (ESI) [ M+H ]]+:573.0. 1 H NMR(400MHz,DMSO-d 6 )δ9.97(s,1H),8.35–8.24(m,2H),7.60(d,J=9.0Hz,1H),7.48(dd,J=8.8,2.6Hz,1H),7.29(d,J=8.7Hz,2H),7.08(d,J=8.4Hz,2H),6.46(t,J=4.1Hz,1H),6.02(s,1H),3.83(s,3H),2.34(m,J=10.8Hz,2H),2.56-2.70(m,2H),1.85(m,2H).
Step 6: synthesis of Compound 2
8-bromo-9- (3-bromocyclohexyl-1-en-1-yl) -1- (4-methoxyphenyl) -2-pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (220.0 mg,0.43mmol,1.0 eq), phenylboronic acid (93.8 mg,0.77mmol,2.0 eq), pd (dppf) Cl 2 (124.1 mg,0.15mmol,0.4 eq) and potassium phosphate (161.0 mg,0.77mmol,2.0 eq) were added to a mixed solvent of 1, 4-dioxane (3.0 mL) and water (0.3 mL), 100After the reaction is completed, diatomite is filtered, filtrate is concentrated, ethyl acetate is added for dilution, water washing, saturated saline water washing and anhydrous sodium sulfate drying are respectively carried out, and finally the filtrate is concentrated. The crude product (80 mg) was obtained by normal phase column separation, petroleum ether and ethyl acetate system, polarity 60%, and the white solid (5 mg) was obtained by preparative separation. LCMS (ESI) [ M+H ] ]+:489.20. 1 H NMR(400MHz,DMSO-d 6 )δ9.69(s,1H),8.53(d,J=2.5Hz,1H),8.36(s,1H),7.86(d,J=8.8Hz,1H),7.70–7.62(m,3H),7.49(t,J=7.6Hz,2H),7.38(s,1H),7.31(d,J=9.0Hz,1H),7.10(d,J=9.0Hz,2H),6.16-6.22(m,1H),6.35-6.40(t,1H),6.43-6.49(dd,1H),2.35–2.26(m,2H),2.43-2.48(m,2H)。
The compounds of table 2 are obtained by reference to the procedure of example 1:
table 2: structure and characterization of Compounds 3 to 7
The compounds of table 3 are obtained by reference to the procedure of example 2:
table 3: structure and characterization of Compounds 8-29, 32-35
/>
/>
/>
Example 30:9- (cyclohex-1-en-1-yl) -1- (4-methoxyphenyl) -8- (1-methyl-1H-benzo [ d ] imidazol-7-yl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (compound 30)
Step 1: synthesis of Compound 30-1
To 15mL of dimethylformamide solvent were added 1-bromo-2-fluoro-3-nitrobenzene (5 g,23.5mmol,1.0 eq), sodium carbonate (4.982 g,47mmol,2.0 eq) and methylamine hydrochloride (1.284 g,28.2mmol,1.7 eq) and reacted at room temperature for 16h. After the completion of the reaction, the reaction mixture was concentrated, and subjected to normal phase column chromatography (ethyl acetate 5%) to give 2-bromo-N-methyl-6-nitroaniline (5.09 g, yield 97.4%) as a red liquid. LCMS (ESI) [ M+H ]] + :231 1 H NMR(400MHz,DMSO)δ7.76(ddd,J=9.8,8.0,1.5Hz,2H),6.70(t,J=8.0Hz,1H),6.33(s,1H),2.70(d,J=3.0Hz,3H).
Step 2: synthesis of Compound 30-2
The compound 2-bromo-N-methyl-6-nitroaniline (2.0 g,8.70mmol,1.0 eq) was added to a solution of glacial acetic acid (20 mL), the temperature was raised to 50℃and reduced iron powder (1.46 g,26.1mmol,3 eq) was added in portions and reacted at 50℃for 1h. After completion of the reaction, the solid residue was filtered off, and reversed-phase column chromatography (25% acetonitrile) was performed to give 6-bromo-N-methylbenzene-1, 2-diamine (510.0 mg, yield 14.1%) as a yellow oil. LCMS (ESI) [ M+H ] ] + :201
Step 3: synthesis of Compound 30-3
6-bromo-N-methylbenzene-1, 2-diamine (510 mg,2.55mmol,1.0 eq) and p-toluenesulfonic acid monohydrate (51.0 mg, 0.292 mmol,0.12 eq) were dissolved in triethyl orthoformate (1.5 mL) and reacted at 85℃for 1h. After the reaction was completed, the reaction mixture was concentrated and subjected to reverse phase column chromatography (acetonitrile 15%) to obtain 7-bromo-1-methyl-1H-benzo [ d ] as a white solid]Imidazole (480.0 mg, 89.6% yield). LCMS (ESI) [ M+H ]] + :211 1 H NMR(400MHz,DMSO)δ8.28(s,1H),7.68(d,J=8.1Hz,1H),7.46(d,J=7.7Hz,1H),7.15(td,J=8.0,1.4Hz,1H),4.10(d,J=1.4Hz,3H).
Step 4: synthesis of Compound 30-4
7-bromo-1-methyl-1H-benzo [ d ]]Imidazole (480.0 mg,2.29mmol,1.0 eq), 4', 5',2 '-octamethyl-2' -bis (1, 3, 2-dioxaborane) (1.74 g,6.87mmol,3.0 eq), pd (dppf) Cl 2 (84.1 mg,0.115mmol,0.05 eq) and potassium acetate (673.3 mg,6.87mmol,3 eq) were dissolved in 1,4 dioxane solution (10 mL) and reacted for 4 hours at 100℃under nitrogen. After the reaction was completed, the filtrate was filtered and concentrated, and the normal phase column chromatography (ethyl acetate 25%) was performed to obtain 1-methyl-7- (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) -1H-benzo [ d ] as a brown solid]Imidazole (375 mg, 63.6% yield) LCMS (ESI) [ M+H)] + :259.
Step 5: synthesis of Compound 30-5
The compound (4, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) -1H-benzo [ d ]]Imidazole (375 mg,1.45mmol,1.0 eq), 8-bromo-2-chloro-9- (cyclohex-1-en-1-yl) -9H-purin-6-ol (477.1 mg,1.45mmol,1.0 eq), pd (dppf) Cl 2 (53.0 mg,0.0725mmol,0.05 eq.) and Cs 2 CO 3 (1.43 g,4.35mmol,3 eq) was added to a mixed solution of 1,4 dioxane (4 mL) and water (1 mL) and reacted at 80℃under nitrogen with stirring for 2h. After completion of the reaction, reverse phase column chromatography (50% acetonitrile) gives 2-chloro-9- (cyclohex-1-en-1-yl) -8- (1-methyl-1H-benzo [ d ] as a brown solid]Imidazol-7-yl) -1, 9-dihydro-6H-purin-6-one (213 mg, yield 38.7%). LCMS (ESI) [ M+H ]] + :381。
Step 6: synthesis of Compound 30-6
The compound 2-chloro-9- (cyclohex-1-en-1-yl) -8- (1-methyl-1H-benzo [ d ]]Imidazol-7-yl) -1, 9-dihydro-6H-purin-6-one (213 mg,0.56mmol,1.0 eq), 2-aminopyridine (79.0 mg,0.84mmol,1.5 eq), pd 2 (dba) 3 (25.6 mg,0.028mmol,0.05 eq.) and Cs 2 CO 3 (551.0 mg,1.68mmol,3 eq) was added to a solution of 1,4 dioxane (5 mL) and reacted at 80℃under nitrogen with stirring for 4h. After completion of the reaction, reverse phase column chromatography (60% acetonitrile) gives 9- (cyclohex-1-en-1-yl) -8- (1-methyl-1H-benzo [ d) as a yellow solid]Imidazol-7-yl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (122 mg, yield 49.7%)
Step 7: synthesis of Compound 30
The compound 9- (cyclohex-1-en-1-yl) -8- (1-methyl-1H-benzo [ d ]]Imidazol-7-yl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (122.0 mg,0.28mmol,1.0 eq), 4-methoxyphenylboronic acid (85.1 mg,0.56mmol,2 eq), copper acetate (76.4 mg,0.42mmol,1.5 eq.) and pyridine (66.4 mg,0.84mmol,3 eq.) were added to a solution of DMF (5 mL) and the reaction stirred at room temperature under oxygen protection for 16H. After completion of the reaction, reverse phase column chromatography (60% acetonitrile) gives 9- (cyclohex-1-en-1-yl) -1- (4-methoxyphenyl) -8- (1-methyl-1H-benzo [ d) as a white solid ]Imidazol-7-yl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (18.5 mg, 12.2% yield) LCMS (ESI) [ M+H] + :545.23。
EXAMPLE 31 8- (6-Aminopyridin-3-yl) -9- (cyclohex-1-en-1-yl) -1- (4-methoxyphenyl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (Compound 31)
Step 1: synthesis of Compound 31-1
To 500mL of the super-dry dichloromethane solvent was added 2, 6-dichloro-9H-urea (60 g,317.46mmol,1.0 eq), p-toluenesulfonic acid monohydrate (6.039 g,476.19mmol,1.5 eq), followed by adding 3, 4-dihydro-2H-pyran (40.05 g,476.19mmol,1.5 eq) dissolved in 100mL of the super-dry dichloromethane solvent slowly with stirring, and reacting at room temperature for 4H. After the reaction was completed, the reaction solution was filtered, the filter cake was washed with methylene chloride, 300ml of 10% sodium carbonate solution was added for extraction, the organic phase was collected, water was further added for extraction, the extracted organic layer was dried over anhydrous sodium sulfate, and the organic phase was concentrated to a solid after drying. Ethyl acetate: petroleum ether = 1:12 to give 2, 6-dichloro-9- (tetrahydro-2H-pyran-2-en) -9H-purine (57.4 g, 86.8% yield) as a white solid. LCMS (ESI) [ M+H ]]+:273 1 H NMR(400MHz,DMSO)δ8.95(s,1H),5.74(dd,J=10.8,2.3Hz,1H),4.06–3.97(m,1H),3.81–3.69(m,1H),2.26(tdd,J=13.3,10.8,4.4Hz,1H),1.99(tt,J=13.2,2.8Hz,2H),1.84–1.69(m,1H),1.59(ddt,J=12.2,8.2,3.7Hz,2H).
Step 2: synthesis of Compound 31-2
2, 6-dichloro-9- (tetrahydro-2H-pyran-2-ene) -9H-purine (5 g,18.38mmol,1.0 eq) was dissolved in 50ml of ultra-dry tetrahydrofuran solvent under nitrogen protection, cooled to-78℃under dry ice ethanol conditions, then 2mol/L lithium diisopropylamide (13.78 ml,27.57mmol,1.5 eq) was slowly added dropwise and stirred for 30min after addition. 1, 2-dibromo-1, 2-tetrachloroethane (8.98 g,27.57mmol,1.5 eq) in 15ml of ultra-dry tetrahydrofuran was then slowly added dropwise, and the reaction was continued at-78℃for 1.5h after the addition. After the reaction was completed, 10ml of saturated ammonium chloride solution was slowly added to quench the reaction solution at a temperature not exceeding-30 ℃. The reaction mixture was concentrated, and subjected to normal phase column chromatography (ethyl acetate 10%) to give 8-bromo-2, 6-dichloro-9- (tetrahydro-2H-pyran-2-en) -9H-purine (2.2554 g yield 35.1%) as a yellow solid LCMS (ESI) [ M+H ]+:351 1 H NMR(400MHz,DMSO)δ5.78–5.67(m,1H),4.66(dd,J=6.5,2.6Hz,1H),3.91–3.68(m,1H),3.36(ddd,J=11.4,7.9,3.6Hz,1H),2.06–1.90(m,1H),1.81–1.69(m,1H),1.60(ddp,J=15.8,6.7,3.5Hz,1H),1.49–1.25(m,2H).
Step 3: synthesis of Compound 31-3
8-bromo-2, 6-dichloro-9- (tetrahydro-2H-pyran-2-ene) -9H-purine (1 g,2.9mmol,1.0 eq) was dissolved in dichloromethane (10 mL) and then 2.5mL trifluoroacetic acid was added under ice-bath conditions and reacted at room temperature for 30min. After the reaction was completed, the reaction solution was concentrated, dissolved in methanol, and triethylamine was added to clarify the solution, followed by reverse phase column chromatography to give 8-bromo-2, 6-dichloro-9H-urea as a pale yellow solid (616 mg, yield 81.1%). LCMS (ESI) [ M+H ]] + :267
Step 4: synthesis of Compound 31-4
8-bromo-2, 6-dichloro-9H-urea (616 mg,2.31mmol,1.0 eq), cyclohexen-1-ylboronic acid (873.2 mg,6.93mmol,3.0 eq), pyridine (547.5 mg,6.93mmol,3 eq), and copper acetate (627.2 mg,3.47mmol,1.5 eq) were reacted for 16 hours at room temperature in an oxygen atmosphere in a 1,4 dioxane solution (10 mL). After the reaction was complete, it was filtered and the mother liquor was chromatographed on reverse phase column (acetonitrile 40%) to give 8-bromo-2-chloro-9- (cyclohex-1-en-1-yl) -9H-purin-6-ol (260 mg, yield 34.2%) as a yellow solid LCMS (ESI) [ M+H ] +:329.
Step 5: synthesis of 2-nitro-5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine
5-bromo-2-nitropyridine (1 g,4.95mmol,1.0 eq.) 4,4', 5',2 '-octamethyl-2' -bis (1, 3, 2-dioxaborane) (1.56 g,6.14mmol,1.24 eq.) Pd (dppf) Cl 2 (182 mg,0.25mmol,0.05 eq.) and potassium acetate (1.44 g,24.8mmol,5.0 eq.) in dioxane (20 mL), N 2 The reaction was allowed to proceed overnight at 90 ℃. After the reaction was completed, the reaction solution was filtered, washed with ethyl acetate, and the mother liquor was retained. After spin drying, purifying by reverse phase column, passing water (1%formic acid solution) and acetonitrile system through column; 50%; the desired product was eluted for 15min to give 2-nitro-5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (707 mg, yield 56%) as a yellow solid. LCMS (ESI) [ M+H ]] + :169. 1 H NMR(400MHz,DMSO-d6)δ8.81(s,1H),8.42(d,J=7.9Hz,1H),8.30(d,J=7.9Hz,1H),1.34(d,J=1.5Hz,12H)
Step 6: synthesis of Compound 31-5
The compound 8-bromo-2-chloro-9- (cyclohex-1-en-1-yl) -9H-purin-6-ol (260 mg,0.79mmol,1.0 eq), 2-nitro-5- (4, 5-tetramethyl-1, 3, 2-dioxaboro-2-yl) pyridine (200.2 mg,1.19mmol,1.5 eq), pd (dppf) Cl 2 (28.9 mg,0.0395mmol,0.05 eq.) and Cs 2 CO 3 (777.4 mg,2.37mmol,3 eq) was added to a mixed solution of 1,4 dioxane (4 mL) and water (1 mL), and the mixture was stirred at 80℃under nitrogen for 2h. After completion of the reaction, reverse phase column chromatography (50% acetonitrile) afforded 2-chloro-9- (cyclohex-1-en-1-yl) -8- (6-nitropyridin-3-yl) -9H-purin-6-ol as a brown solid (190 mg, yield 64.4%). LCMS (ESI) [ M+H ]]+:373
Step 7: synthesis of Compound 31-6
The compound 2-chloro-9- (cyclohex-1-en-1-yl) -8- (6-nitropyridin-3-yl) -9H-purin-6-ol (190 mg,0.51mmol,1.0 eq), 2-aminopyridine (71.9 mg,0.77mmol,1.5 eq), pd 2 (dba) 3 (23.3 mg,0.0225mmol,0.05 eq.) and Cs 2 CO 3 (501.8 mg,1.53mmol,3 eq) was added to a solution of 1,4 dioxane (5 mL) and reacted at 80℃under nitrogen with stirring for 4h. After completion of the reaction, reverse phase column chromatography (60% acetonitrile) gave 9- (cyclohex-1-en-1-yl) as a yellow solid-8- (6-nitropyridin-3-yl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (155 mg, yield 70.5%). LCMS (ESI) [ M+H ]]+:431
Step 8: synthesis of Compound 31-7
The compound 9- (cyclohex-1-en-1-yl) -8- (6-nitropyridin-3-yl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (155 mg,0.36mmol,1.0 eq), 4-methoxyphenylboronic acid (109.4 mg,0.72mmol,2 eq), copper acetate (98.3 mg,0.54mmol,1.5 eq.) and pyridine (85.3 mg,1.08mmol,3 eq.) were added to a solution of DMF (5 mL) and the reaction was stirred at room temperature under oxygen for 16H. After completion of the reaction, reverse phase column chromatography (60% acetonitrile) afforded 9- (cyclohex-1-en-1-yl) -1- (4-methoxyphenyl) -8- (6-nitropyridin-3-yl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (90.0 mg, yield 46.6%) as a yellow solid. LCMS (ESI) [ M+H ] +:537.
Step 9: synthesis of Compound 31
The compound 9- (cyclohex-1-en-1-yl) -1- (4-methoxyphenyl) -8- (6-nitropyridin-3-yl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (90.0 mg,0.168mmol,1.0 eq) was added to a solution of glacial acetic acid (5 mL), heated to 50℃and reduced iron powder (47.1 mg,0.84mmol,5 eq) was added in portions and reacted at 50℃for 1H. After completion of the reaction, the solid residue was filtered off, and reversed-phase column chromatography (60% acetonitrile) to give 8- (6-aminopyridin-3-yl) -9- (cyclohex-1-en-1-yl) -1- (4-methoxyphenyl) -2- (pyridin-2-ylamino) -1, 9-dihydro-6H-purin-6-one (12.0 mg, yield 14.1%) as a white solid. LCMS (ESI) [ M+H ] +:507.2.
The compounds of table 4 are obtained by the method of reference example 31:
table 4: structure and characterization of Compounds 36 and 37
The procedure for the preparation of compound 36 was the same as in example 31, except that there was one more halogenation step.
Experimental example 1: binding Capacity test of Compounds of the invention to mat2a protein
The purpose of the experiment is as follows: detection of binding Capacity of Compounds to MAT2A protein by CETSA Experimental method
Background principle: CETSA assay is a molecular assay that measures the affinity of a drug for a target protein. The principle is that after the medicine is combined with the target protein, the structure is more stable. Using a cell or tissue sample at the candidate drug, if the candidate drug is an inhibitor of MAT2A, the candidate drug can be combined with MAT2A, so that MAT2A protein becomes more stable, after the sample is subjected to heat treatment, MAT2A protein in the sample is easier to detect by a specific antibody, and MAT2A protein is easier to detect by a Western blot experiment; conversely, the stability of MAT2A protein after heating will be worse and the amount of protein detected will be lower. Thereby evaluating the binding capacity of the drug to the target protein for screening of MAT2A protein inhibitors.
The specific experimental process comprises the following steps:
taking HCT116 cells in logarithmic growth phase (cell survival rate > 90%), washing the cells 3 times by PBS, and centrifuging for 2min at 2000 g; lysing with a cell lysate containing a protease inhibitor PMSF on ice for 30min; protein samples were assayed for concentration using BCA kit. Incubating the samples for 30min by using the candidate drugs, the control drugs and the control reagents respectively, and heating the set 10 temperature points of each group of samples; recovering room temperature, centrifuging the sample with 20000g, and collecting the supernatant; protein samples were denatured using sample buffer at 100℃for 10 min. After the sample is restored to room temperature, performing western blot detection on the sample; the protein loading was controlled at 20ug. After the mutation temperature is determined, the concentration gradient of the compound is set to be 9 points generally, the sample is incubated, and western blot detection is carried out by the same operation. Protein electrophoresis: the concentrated gel voltage is set to 60v, and the separation gel voltage is set to 120v; after the electrophoresis, the electrophoresis was started to be performed. The condition of the electric transfer is set to 250mA for 2 hours; blocking with 5% BSA for 1h; adding a specific 1 antibody, and incubating on a shaking table at 4 ℃ overnight; TBST is washed for 4 times, each time for 2.5min; incubating the mixture for 2 hours on a shaking table at room temperature; TBST is washed for 4 times, each time for 2.5min; development was performed using ECL to detect the amount of TYK2 protein expressed in different groups and at various temperature points. EC50 was calculated by converting the western blot bands by image J and GraphPad software.
EC50 is the half maximal effector concentration (concentration for 50%of maximal effect,EC50), which refers to the concentration of drug that is effective in 50% of individuals. AG270 (compound 153 reported in CN 201780066270.4) of An Jiao s pharmaceutical limited was used as a positive reference compound.
EC50 values for each compound were classified according to the following description:
"+" indicates an EC50 value greater than 100 μm;
"++" indicates that the EC50 value is less than 100. Mu.M and greater than 10. Mu.M;
"+". ++'s representation of EC50 the value is less than 10. Mu.M.
TABLE 5 EC50 results
/>
EC50 experimental data show that the compound of the invention has better binding ability with MAT2A protein, and compared with a positive control AG270 (prepared by referring to the preparation method of the compound 153 reported in CN 201780066270.4), the binding ability of the compound of the invention with MAT2A protein is equivalent, even stronger.
Experimental example 2: the compound of the invention is used for preparing HCT116 MTAP -/- Determination of cell proliferation
The purpose of the experiment is as follows: the purpose of this test case was to test the compound pair HCT116 MTAP -/- Cell proliferation.
Background principle: methionine adenosyltransferase 2A (MAT 2A) is considered a synthetic lethal target for cancers in which the methylthioadenosine phosphorylase (MTAP) gene is deleted, adjacent to the CDKN2A tumor suppressor, and co-deleted with CDKN2A in about 15% of cancers. Thus, by detecting the compound pair HCT116 MTAP -/- The inhibition rate of cell proliferation is used for screening MAT2A protein inhibitor.
The specific experimental process comprises the following steps:
HCT116 MTAP knockout cells were constructed and monoclonal was selected. HCT116 MTAP to be in logarithmic growth phase -/- And WT cells, seeded in 96-well plates at 90uL per well, 1000 per well, and incubated overnight at 37 ℃. The next day, 10. Mu.l of the compound (final DMSO concentration 1%) was added and incubated in an incubator at 37℃for 10 days. On day 10, the old medium was aspirated, 110ul medium (medium to CCK8 ratio 100:10) was added and incubated at 37℃for 1-4h. Absorbance was measured at 450nM, IC50 was calculated by GraphPad software treatment and compounds were screened by comparison with positive drug.
IC50 (half maximal inhibitory concentration) refers to the half-inhibitory concentration of the antagonist being measured. It indicates that a certain drug or substance (inhibitor) is inhibiting half of a certain biological process (or a certain substance contained in the process, such as an enzyme, a cellular receptor or a microorganism). AG270 of An Jiao s pharmaceutical limited was used as a positive reference compound.
The test results are shown in Table 6 below, wherein the IC50 values of the compounds are classified according to the following description:
+++ is less than 100nM of the total of all the above-mentioned materials, ++ between 100nM and 10. Mu.M, + is greater than 10 μm.
The test results are shown in Table 6 below:
TABLE 6 IC50 experimental data
/>
The results show that the compound can inhibit HCT116 MTAP-null cells, and the IC50 value reaches the nM level, which is equivalent to or smaller than that of a positive control medicine AG270. This strong inhibition is of great therapeutic interest for the treatment of conditions or diseases associated with MAT2A inhibition.
Experimental example 3: determination of the functional Effect of the Compounds of the invention on MAT2A protease
The purpose of the experiment is as follows: the purpose of this test case was to test the ability of the compounds to inhibit MAT2A protease function.
Background principle: met A2A, a metabolic enzyme, plays an important role in metabolism and epigenetic science because it is the primary producer of the universal methyl donor S-adenosylmethionine (SAM). ATP and L-Met under the action of MAT2A produce SAM and phosphate groups. Thus, after incubation of the compound, the ability of the compound to inhibit MAT2A enzyme function was evaluated by detecting the amount of SAM produced for use in screening MAT2A protein inhibitors.
The specific experimental process comprises the following steps:
MAT2A protein expression: full length MAT2A was cloned into pET24N vector with an N-terminal (His) 6x tag and a Tobacco Etch Virus (TEV) protease cleavage site. The constructed vector was transformed into E.coli BL21 (DE 3), shaken to OD 0.6, and incubated with 1mM IPTG at 18℃for 16h. Collecting thallus, ultrasonic crushing, centrifuging to obtain supernatant, purifying protein with Ni-NTA, and dialyzing to determine protein concentration and purity. SAM assay: the reaction system: 91-x uL of KCl 50mM Tris HCl pH 7.5,1.5uL (10/3M), 1.5uL (1M) MgCl2,1uL (100 mM) ATP,1uL (80 mM) L-Met,1uL (30 mM PH7.67) EDTA,1uL5% BSA,2uL of the DMSO-solubilized drug, and x uL of MAT2A protein were added sequentially. The experimental groups were prepared with different drug concentrations, 2uL (100 x) was taken out, added to the reaction system, and reacted at 37 ℃ for 18h, and solvent control group and blank control group were set, respectively. The reaction was terminated, 40uL of the system was removed, and the reaction was quenched by adding 4uL of 10% SDS. IC50 was calculated by GraphPad software treatment and compounds were screened by comparison with positive drug.
The test results are shown in Table 7 below, wherein the IC50 values of the compounds are classified according to the following description:
small+++. At a concentration of 10nM, ++ between 10nM and 1. Mu.M, + is greater than 1 μm.
The test results are shown in Table 7 below:
TABLE 7 IC50 experimental data
/>
The results show that the compound has very strong inhibition effect on MAT2A protease function, and the IC50 values reach nM level and are smaller than that of a positive control medicine AG270. This strong inhibition is of great therapeutic interest for the treatment of conditions or diseases associated with MAT2A inhibition.
The above embodiments are merely representative. From the above examples, it can be seen that the compounds of the present invention are ideal, highly potent MAT2A inhibitors, and are expected to be useful in the treatment or prevention of disorders or diseases associated with MAT2A inhibition.
The foregoing is only a preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be able to apply equivalents and modifications according to the technical scheme and the inventive concept thereof within the scope of the present invention.
Claims (5)
1. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof,
wherein:
R 3 selected from methoxyphenyl groups;
R 5 selected from the group consisting of The groups are optionally substituted with one or more amino, methyl, methoxy, hydroxy, halogen, cyano groups.
2. A compound or a pharmaceutically acceptable salt thereof, which is:
3. a pharmaceutical composition comprising a compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant.
4. Use of a compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 3, in the manufacture of a medicament for treating a disease or disorder in a subject suffering from said disease or disorder, wherein said disease or disorder is mediated through overexpression of MAT2A, said disease or disorder being cancer.
5. The pharmaceutical use according to claim 4, wherein the cancer is characterized by a decrease or a deletion of the expression of the methylthioadenosine phosphorylase (MTAP) gene, a deletion of the MTAP gene, or a decrease in MTAP protein function.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311532058.6A CN117777134A (en) | 2022-12-19 | 2022-12-19 | Polycyclic compounds as MAT2A inhibitors |
CN202211634333.0A CN116425751B (en) | 2022-12-19 | 2022-12-19 | Polycyclic compounds as MAT2A inhibitors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211634333.0A CN116425751B (en) | 2022-12-19 | 2022-12-19 | Polycyclic compounds as MAT2A inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311532058.6A Division CN117777134A (en) | 2022-12-19 | 2022-12-19 | Polycyclic compounds as MAT2A inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116425751A CN116425751A (en) | 2023-07-14 |
CN116425751B true CN116425751B (en) | 2024-01-23 |
Family
ID=87093179
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211634333.0A Active CN116425751B (en) | 2022-12-19 | 2022-12-19 | Polycyclic compounds as MAT2A inhibitors |
CN202311532058.6A Pending CN117777134A (en) | 2022-12-19 | 2022-12-19 | Polycyclic compounds as MAT2A inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311532058.6A Pending CN117777134A (en) | 2022-12-19 | 2022-12-19 | Polycyclic compounds as MAT2A inhibitors |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN116425751B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024086939A1 (en) * | 2022-10-26 | 2024-05-02 | Inversago Pharma Inc. | Purine compounds, compositions comprising them and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102105474A (en) * | 2008-05-30 | 2011-06-22 | 健泰科生物技术公司 | Purine PI3K inhibitor compounds and methods of use |
CN103261200A (en) * | 2010-09-13 | 2013-08-21 | 阿迪维纳斯疗法有限公司 | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
CN104640861A (en) * | 2012-01-31 | 2015-05-20 | 药品循环公司 | Purinone compounds as kinase inhibitors |
CN106414446A (en) * | 2014-03-13 | 2017-02-15 | 新加坡科技研究局 | Fused pyrimidine-based hydroxamate derivatives |
US11084798B1 (en) * | 2018-12-10 | 2021-08-10 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
-
2022
- 2022-12-19 CN CN202211634333.0A patent/CN116425751B/en active Active
- 2022-12-19 CN CN202311532058.6A patent/CN117777134A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102105474A (en) * | 2008-05-30 | 2011-06-22 | 健泰科生物技术公司 | Purine PI3K inhibitor compounds and methods of use |
CN103261200A (en) * | 2010-09-13 | 2013-08-21 | 阿迪维纳斯疗法有限公司 | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
CN104640861A (en) * | 2012-01-31 | 2015-05-20 | 药品循环公司 | Purinone compounds as kinase inhibitors |
CN106414446A (en) * | 2014-03-13 | 2017-02-15 | 新加坡科技研究局 | Fused pyrimidine-based hydroxamate derivatives |
US11084798B1 (en) * | 2018-12-10 | 2021-08-10 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
Non-Patent Citations (1)
Title |
---|
A Patent Review of MAT2a Inhibitors (2018-2021).;Atkinson Stephen J;Expert opinion on therapeutic patents;1-10 * |
Also Published As
Publication number | Publication date |
---|---|
CN116425751A (en) | 2023-07-14 |
CN117777134A (en) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10774070B2 (en) | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors | |
US9737516B2 (en) | Bicyclic heterocycles as bet protein inhibitors | |
US9918990B2 (en) | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | |
EP3019502B1 (en) | Tricyclic heterocycles as bet protein inhibitors | |
CN111712498A (en) | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | |
US20150148372A1 (en) | Bicyclic heterocycles as bet protein inhibitors | |
CN112724145A (en) | Pyrazine derivatives for inhibiting SHP2 activity | |
WO2016193844A1 (en) | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme | |
IL284326B1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
WO2020125759A1 (en) | Compound as wnt signal pathway inhibitor and medical use thereof | |
CN109988165B (en) | Heteroaromatic compound as PI3K/mTOR kinase regulator and preparation method and application thereof | |
CN116425751B (en) | Polycyclic compounds as MAT2A inhibitors | |
CN113336747A (en) | Novel HPK1 inhibitor and preparation method and application thereof | |
CN109721600A (en) | A kind of nitrogenous fused ring compound and its preparation method and application | |
CN111989332B (en) | Macrocyclic compounds as CDK inhibitors, their preparation and their use in medicine | |
CN108947879B (en) | PRMT I type inhibitor and preparation method and application thereof | |
CN115260187A (en) | Pyridone compounds and uses thereof | |
CN115960098A (en) | Preparation method and application of nitrogen-containing fused ring compounds | |
CN112300173A (en) | Nitrogen-containing polycyclic compounds, preparation method and application | |
WO2020156319A1 (en) | N-formamide derivative, preparation method therefor and medical use thereof | |
CN115698005B (en) | Fused ring AhR inhibitors | |
CN116425721B (en) | Bicyclic compounds as MAT2A inhibitors | |
CN115141202A (en) | Pyrimidopyrazinone compounds and uses thereof | |
CN109384793B (en) | Thiol compound with HDAC6 inhibitory activity and application thereof | |
CN115448921A (en) | Imidazolidinone pyrimidone compounds and application thereof in treatment of HsClpP mediated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |